Who We Are
Commercial advice rooted in financial discipline
Commercial questions arrive wrapped in strategy language that obscures the actual choice. P&L complexity masks where value is leaking. Pricing architecture is never revisited. Growth looks profitable while consuming cash. Portfolio drag is invisible.
We read the numbers with skepticism. We surface what the numbers are hiding. We test whether assumptions actually hold under pressure. We force downside scenarios. We identify where capital is trapped.
The result is clarity on what the decision actually is, which assumptions determine the answer, and what needs to change for it to work.
Where We Add Value
The recurring distortions
These are the problems we see repeatedly. They usually get missed because numbers obscure them or because what the organization believes diverges from what's actually happening.
Pricing usually doesn't match what the market will bear
Most companies price relative to cost, not market value. Hidden discount structures reward negotiation over value. The gap between list price and realized price consumes 15-20 percent of margin on a business earning 15 points—and most companies never see it because they don't look at realized price by customer or transaction.
Contribution by product and channel is almost always invisible
Standard P&L obscures where profit actually comes from. Volume growth hides contribution collapse. A business might be growing revenues 10 percent while contribution per unit falls. You cannot make capital allocation decisions without seeing this.
Growth expansion assumes facts that are never tested
Revenue ramps, cost structures, market adoption timelines—growth plans are built on assumptions that rarely get stress tested. Cash burn is disconnected from revenue scaling. A business that looks cash positive in the base case can destroy shareholder value if the upside fails. Bad expansion decisions can consume years of accumulated profit.
Fixed cost structures are determined by history, not economics
Capacity decisions made five years ago now determine vulnerability to revenue pressure. Most companies don't model what happens if revenue slows 20 percent. A business with 35 percent fixed costs cannot survive sustained revenue pressure. You discover this too late.
Acquisitions depend on assumptions that look credible until they aren't
Deal teams are motivated to make the deal work. Strategic synergies are assumed rather than proven. Integration costs are underestimated. The difference between a good deal and a bad one is almost always determined at the due diligence stage, not in execution.
Capital allocation reflects momentum more than return expectations
Competing investments are rarely evaluated consistently. Hurdle rates are unenforced or inconsistent. A business allocating capital at 8 percent return when its cost of capital is 10 percent destroys shareholder value every year. The gap compounds.
Commercial Patterns
Where these problems repeat
Recurring patterns across sectors where contribution gets misread, capital gets trapped, incentives distort decisions, and growth narratives diverge from cash economics.
Software and SaaS
Unit economics look clean until you disaggregate by cohort. A 10-year-old cohort might be profitable while newer cohorts are destroying value. Churn curves are embedded in valuation but often invisible in strategy. Pricing power gets assumed but tested by competitor entry. Revenue growth masks contribution collapse.
Manufacturing and Industrial
Capacity and fixed cost decisions made five years ago now determine vulnerability to revenue pressure. A business cannot survive a 20-30 percent revenue decline if 40 percent of costs are fixed. Investment decisions assume full capacity but downturns empty it. The structural cost problem is usually discovered too late.
Financial Services
Profitability is driven more by customer mix than operational excellence. Payer mix determines realized price independent of list price. Capital requirements often constrain strategy more than market position does. Moving the wrong customers usually destroys margin faster than pricing power creates it.
Healthcare and Pharma
Portfolio economics are opaque. A few large bets determine returns across the entire pipeline. Clinical timelines compress timelines for capital allocation decisions. R&D spending is enormous but returns are concentrated. Capital often sits unproductively in programs that will never reach market.
How we work
Three things we focus on
We pressure test the assumptions, downside, and economic logic in your decision. This is how we think.
Separate what's carrying the decision from what's decorative
Every recommendation depends on a few assumptions doing most of the work. We identify which ones matter. We test them against market logic and evidence. We model what happens if the critical assumption is wrong by 20, 40, or 60 percent. That's where the real risk lives.
Force the downside into the room
The downside case is not pessimism. It's an interrogation of what can credibly go wrong. Slower growth. Margin compression. Churn. Competitive response. We ask whether your recommendation still makes sense if downside becomes more likely than your base case. Most companies skip this. That's usually where the bad decisions hide.
Identify what changes shape once the trade-offs are explicit
Once assumptions and downside are clear, the decision often looks different. The binary frame doesn't hold. Intermediate options become visible. Different timing. Partial investment. Staged entry. We help identify variations that reduce risk without requiring heroic assumptions. Then we stay involved through execution because that's where decisions fail.